Source comparison
CJC-1295 vs IGF-1 LR3 — Mechanisms, Results & Real Differences
Research from the University of Arizona College of Medicine found that CJC-1295 extends growth hormone half-life from eight minutes to eight days. Not by injecting GH directly, but by amplifying the pituitary's natural secretory bursts. IGF-1 LR3, by contrast
This comparison does not assign a generated winner or score.
- Research from the University of Arizona College of Medicine found that CJC-1295 extends growth hormone half-life from eight minutes to eight days. Not by injecting GH directly, but by amplifying the pituitary's natural secretory bursts. IGF-1 LR3, by contrast, doesn't touch the pituitary at all. It's a synthetic analogue of insulin-like growth factor that binds poorly to IGF-binding proteins, allowing it to remain active in circulation 2–3× longer than endogenous IGF-1. The difference between CJC-1295 and IGF-1 LR3 is the difference between turning up the volume on your body's existing growth axis and introducing a compound that operates outside it entirely.
- Our team has worked with researchers navigating peptide selection for tissue growth studies, anabolic signalling investigations, and recovery protocol design. The question we hear most often isn't 'which peptide is stronger'. It's 'which one does what I actually need without triggering the feedback suppression I'm trying to avoid.'
- What is the difference between CJC-1295 and IGF-1 LR3?
- CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue that extends endogenous GH pulsatility by binding to GHRH receptors on somatotroph cells in the anterior pituitary. IGF-1 LR3 is a recombinant form of insulin-like growth factor-1 with an arginine substitution at position 3, reducing its affinity for IGF-binding proteins and extending its half-life to approximately 20–30 hours compared to 12–15 hours for native IGF-1. CJC-1295 works within the hypothalamic-pituitary axis; IGF-1 LR3 bypasses it. One amplifies natural secretion. The other replaces it.
- The simplest framing: CJC-1295 turns the dial up on your existing growth hormone machinery. IGF-1 LR3 introduces a signal your body didn't produce on its own. Both drive anabolic outcomes. Muscle protein synthesis, lipolysis, glycogen sparing, connective tissue repair. But through entirely different upstream pathways. The rest of this piece covers how each mechanism works at the receptor level, what that means for dosing and timing, and which structural differences matter in research protocol design.